Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GONAL-F RFF vs BRAVELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular growth and maturation and spermatogenesis.
Bravelle (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth and maturation by binding to FSH receptors on granulosa cells, increasing c AMP production and promoting follicular development.
Induction of ovulation in anovulatory women,Controlled ovarian hyperstimulation for assisted reproductive technologies,Spermatogenesis induction in hypogonadotropic hypogonadism (with h CG)
Ovulation induction in anovulatory women with polycystic ovary syndrome (PCOS),Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF)
Subcutaneous injection, initially 75-150 IU once daily for 5-7 days for ovulation induction. For controlled ovarian hyperstimulation, 75-300 IU once daily starting day 2 or 3 of cycle. Dose adjusted based on response.
For ovulation induction: 150 IU subcutaneously or intramuscularly once daily for 5 days, starting on day 3 or 5 of menstrual cycle. For controlled ovarian hyperstimulation: 150-225 IU subcutaneously or intramuscularly once daily for 5-7 days, then adjust based on response.
Terminal elimination half-life: approximately 24-30 hours (range 24-36 h) following subcutaneous administration; supports once-daily dosing regimen.
Terminal elimination half-life approximately 5-6 hours in healthy adults. Extended in renal impairment (up to 24 hours with Cr Cl <30 m L/min).
Primarily hepatic via proteolytic degradation and renal clearance
Primarily metabolized in the liver via renal excretion; metabolic pathways not fully characterized.
Renal excretion: approximately 70% of the dose is eliminated in urine as intact hormone and metabolites; fecal excretion is negligible (<5%).
Primarily renal: 95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal: 5% eliminated via feces.
Approximately 95% bound to plasma proteins, primarily albumin and sex hormone-binding globulin (SHBG).
Approximately 10-20% bound to plasma proteins (albumin and α-1 acid glycoprotein).
Volume of distribution: 6-10 L/kg, indicating extensive distribution into extracellular fluid and tissues (e.g., ovaries).
Approximately 0.3-0.5 L/kg. Distributing primarily in extracellular fluid; does not extensively penetrate tissues.
Subcutaneous: approximately 70-80% (relative to intravenous administration); intramuscular: 100% (absolute bioavailability for Gonal-f RFF not explicitly reported, but similar to follitropin alfa).
Subcutaneous: 90-95% bioavailable relative to intramuscular route. Oral: not clinically used due to enzymatic degradation.
No specific dose adjustment provided by manufacturer. GFR <30 m L/min: use with caution due to limited data.
No specific guidelines exist for GFR-based dose modifications; use with caution in severe renal impairment (Cr Cl <30 m L/min) and monitor for adverse effects.
No specific dose adjustment provided by manufacturer. Child-Pugh Class C: use with caution; no established guidelines.
No specific guidelines exist for Child-Pugh based modifications; use with caution in severe hepatic impairment and monitor for adverse effects.
Not indicated for use in pediatric patients. Safety and efficacy not established.
Not indicated for use in pediatric patients; safety and efficacy not established.
Not indicated for use in geriatric patients. Safety and efficacy not established.
Not indicated for use in geriatric patients; safety and efficacy not established.
None
Bravelle should only be used by physicians who are experienced in infertility treatment and can manage potential serious adverse events, including ovarian hyperstimulation syndrome (OHSS) and multiple gestations.
Ovarian hyperstimulation syndrome (OHSS),Ovarian torsion,Multiple pregnancy,Pulmonary embolism and thromboembolic events,Ovarian enlargement,Ectopic pregnancy,Congenital malformations (risk similar to general population)
Ovarian enlargement and ovarian hyperstimulation syndrome (OHSS) – can lead to serious complications; discontinue treatment if OHSS is suspected.,Multiple gestations – increased risk of multiple births.,Ovarian torsion – report sudden abdominal pain.,Pulmonary and vascular complications – thromboembolic events; discontinue if suspected.,Ectopic pregnancy and spontaneous abortion – higher rates in ART patients.,Neoplasms – risk of ovarian neoplasms with repeated use.
Hypersensitivity to FSH or any excipients,High levels of FSH indicating primary gonadal failure,Uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary),Sex hormone dependent tumors (ovarian, breast, uterus, testis, hypothalamus, pituitary),Abnormal uterine bleeding of undetermined origin,Pregnancy and lactation
Hypersensitivity to urofollitropin or any component,High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Known or suspected pregnancy,Ovarian cyst or enlargement of undetermined origin,Abnormal uterine bleeding of undetermined origin,Sex hormone-dependent tumors (e.g., breast, uterus, ovary)
No significant food interactions. Maintain a balanced diet; avoid excessive alcohol intake as it may impair fertility. Caffeine in moderation (≤200 mg/day) is generally acceptable, but discuss with your healthcare provider.
No known food interactions. Maintain normal diet and hydration. Avoid alcohol as it may exacerbate side effects like nausea.
Fetal risk cannot be ruled out. Category X: contraindicated in pregnancy due to risk of multiple gestation and ectopic pregnancy; no systematic evidence of teratogenicity but animal studies show post-implantation loss and fetal abnormalities at high doses.
Pregnancy Category X. Urofollitropin is contraindicated in pregnant women due to risk of fetal harm. First trimester: Ovarian hyperstimulation syndrome (OHSS) and multiple gestations. Second and third trimesters: No direct fetal effects reported, but risks associated with multiple gestation (preterm birth, low birth weight). Maternal OHSS may lead to thromboembolism.
No human data; M/P ratio unknown. Excretion in breast milk unknown; caution advised due to potential for serious adverse effects in infant.
Urofollitropin is not indicated for use during lactation. No data on excretion in human milk, M/P ratio not established. Use during breastfeeding is contraindicated due to potential for adverse effects on infant hormone levels.
Contraindicated in pregnancy; no dosing adjustments applicable as therapy is discontinued upon confirmed pregnancy.
No dose adjustment applicable as therapy is discontinued upon confirmed pregnancy. No pharmacokinetic data during pregnancy; drug is not used after conception due to contraindication.
GONAL-F RFF (follitropin alfa) is a recombinant follicle-stimulating hormone (FSH) used for ovulation induction and controlled ovarian hyperstimulation. Administer subcutaneously; rotate injection sites to prevent lipodystrophy. Adjust dose based on ovarian response monitoring (ultrasound and estradiol levels). Risk of ovarian hyperstimulation syndrome (OHSS) requires vigilance; withhold h CG if estradiol >3000 pg/m L or >20 follicles ≥14 mm. Use with Gn RH agonist or antagonist to prevent premature LH surge. Prefilled syringe ensures accurate dosing; do not mix with other drugs. Store refrigerated, but may be stored at room temperature (≤25°C) for up to 28 days.
BRAVELLE (urofollitropin) is a purified FSH product used for controlled ovarian hyperstimulation. Administer subcutaneously; rotate injection sites. Monitor estradiol levels and follicle growth via ultrasound. Risk of ovarian hyperstimulation syndrome (OHSS); consider using Gn RH antagonist protocols to reduce risk. Do not administer if patient has high baseline FSH levels (>15 IU/L) indicating poor ovarian reserve.
Inject exactly as prescribed, preferably at the same time daily.,Rotate injection sites (abdomen, thigh) to avoid lumps or pain.,Do not skip doses; contact your doctor if you miss a dose.,Report symptoms of OHSS: severe pelvic pain, bloating, nausea, rapid weight gain, or decreased urination.,Avoid pregnancy tests until instructed, as the medication may cause false results.,Store unopened vials in the refrigerator. Once opened, use within 28 days if kept at room temperature.
Teach proper injection technique and site rotation (abdomen, thigh).,Report immediately if severe pelvic pain, nausea, vomiting, or rapid weight gain occurs (OHSS signs).,Avoid intercourse until instructed to prevent multiple pregnancy.,Inform of multiple pregnancy risk (especially twins).,Store vials in refrigerator (2-8°C) and protect from light.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GONAL-F RFF vs BRAVELLE, answered by our medical review team.
GONAL-F RFF is a Gonadotropin that works by Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular growth and maturation and spermatogenesis.. BRAVELLE is a Gonadotropin that works by Bravelle (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth and maturation by binding to FSH receptors on granulosa cells, increasing c AMP production and promoting follicular development.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GONAL-F RFF and BRAVELLE depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GONAL-F RFF is: Subcutaneous injection, initially 75-150 IU once daily for 5-7 days for ovulation induction. For controlled ovarian hyperstimulation, 75-300 IU once daily starting day 2 or 3 of cycle. Dose adjusted based on response.. The standard adult dose of BRAVELLE is: For ovulation induction: 150 IU subcutaneously or intramuscularly once daily for 5 days, starting on day 3 or 5 of menstrual cycle. For controlled ovarian hyperstimulation: 150-225 IU subcutaneously or intramuscularly once daily for 5-7 days, then adjust based on response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GONAL-F RFF and BRAVELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GONAL-F RFF is classified as Category C. Fetal risk cannot be ruled out. Category X: contraindicated in pregnancy due to risk of multiple gestation and ectopic pregnancy; no systematic evidence of teratogenicity but anima. BRAVELLE is classified as Category C. Pregnancy Category X. Urofollitropin is contraindicated in pregnant women due to risk of fetal harm. First trimester: Ovarian hyperstimulation syndrome (OHSS) and multiple gestatio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.